ProfileGDS5678 / 1417752_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 70% 70% 71% 69% 65% 71% 70% 66% 72% 73% 70% 71% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4172571
GSM967853U87-EV human glioblastoma xenograft - Control 24.4069270
GSM967854U87-EV human glioblastoma xenograft - Control 34.3738570
GSM967855U87-EV human glioblastoma xenograft - Control 44.5525371
GSM967856U87-EV human glioblastoma xenograft - Control 54.2959769
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9680165
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4213771
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3533470
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9588866
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6065672
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6580573
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3988870
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4337771
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3680770